View:

  • 100 Questions and Answers About Myeloma

    By Asad Bashey

    Our Price: $21.95
    • Format: Paperback
    • ISBN-13: 9781449689315
    • Publisher: Jones & Bartlett Learning
    • Published: December 2012
    Bashey (director of clinical research, Blood and Marrow Transplant Group of Georgia at Northside Hospital), Abonour (chief, Multiple Myeloma Program at the Indiana U. Melvin and Bren Simon Cancer Center), and Huston, a best-selling author diagnosed with myeloma, have created this book for patients with myeloma, their relatives and friends. The book answers one hundred questions within seven parts: the basics, diagnosing and staging, treatment options, side effects and complications of treatment, stem cell transplantation, if treatment fails, and advocacy and support. The appendix provides information and resources. The book includes a glossary. Annotation ©2013 Book News, Inc., Portland, OR (booknews.com)
  • Non Myeloablative Allogeneic Transplantation

    By Asad Bashey

    Our Price: $169.99
    • Format: Hardcover
    • ISBN-13: 9780792376460
    • Publisher: Springer Verlag
    • Published: March 2002
  • Non-myeloablative Allogeneic Transplantation

    By Asad Bashey

    Our Price: $149.99
    • Format: Paperback
    • ISBN-13: 9781461353041
    • Publisher: Springer Verlag
    • Published: April 2013
    Non-myeloablative allogeneic stem cell transplantation (also known as mini-transplantation or reduced-intensity conditioning transplantation) is a major advance in the field of hematopoietic transplantation within the last 5 years. This approach uses non-cytotoxic or reduced-intensity cytotoxic therapy to prepare patients for allografting of hematopoietic stem cells and lymphocytes. It has the potential to deliver the potent anti-tumor immunotherapy and bone marrow replacement capacity of allogeneic stem cell transplantation to patients with reduced treatment-related morbidity and mortality. It may also enable allogeneic transplantation in patients who would be considered ineligible for conventional transplants because of co-morbidity or advanced age. However, this approach may necessitate more careful monitoring of post-transplant chimerism and malignant disease-status than is usual with conventional allografting. There is also controversy regarding the best preparative regimen and graft-versus-host disease prophylaxis to use.

View: